Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Bolt Biotherapeutics (BOLT) Equity Ratio (2020 - 2025)

Bolt Biotherapeutics' Equity Ratio history spans 6 years, with the latest figure at 0.49 for Q3 2025.

  • For Q3 2025, Equity Ratio fell 25.1% year-over-year to 0.49; the TTM value through Sep 2025 reached 0.49, down 25.1%, while the annual FY2024 figure was 0.57, 18.64% down from the prior year.
  • Equity Ratio for Q3 2025 was 0.49 at Bolt Biotherapeutics, down from 0.51 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.93 in Q1 2021 and bottomed at 0.49 in Q3 2025.
  • The 5-year median for Equity Ratio is 0.75 (2023), against an average of 0.72.
  • The largest annual shift saw Equity Ratio skyrocketed 136.05% in 2021 before it decreased 25.59% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.81 in 2021, then fell by 7.38% to 0.75 in 2022, then fell by 6.28% to 0.71 in 2023, then dropped by 18.64% to 0.57 in 2024, then fell by 14.05% to 0.49 in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Equity Ratio are 0.49 (Q3 2025), 0.51 (Q2 2025), and 0.55 (Q1 2025).